Generex Biotechnology Corp. (fka GNBTQ)

[RoswellChamp]

The final results for the AE-37 Phase II Trial which are to be released for the ASCO Conference and then presented to the meeting will not be "bad." Generex published the preliminary results late last year and then , in February I believe, announced that the final results were "consistent" with the "preliminary results previously released." This was at the time they announced their selection as an ASCO presenter.

So the big issue now is not "what are the results?" but how are they received? Will the impression on reviewers, analysts, peers, etc., be favorable? Will these folks say good things about the results? That's what you want to be looking for!